

Balloon Catheter use for Sinus Ostial Dilation and Septoplasty

Policy # 00292

Original Effective Date: 04/13/2011

Current Effective Date: 05/01/2026

Retired Date: 12/15/2012

Returned to Active Status: 12/01/2015

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Investigational or experimental services are not covered. This includes any drug, device, procedure, or service provided under the investigational arm of a clinical trial or clinical study. These services are excluded from coverage under benefits.

Note: Functional Endoscopic Sinus Surgery for Chronic Rhinosinusitis is addressed separately in medical policy 00711.

Note: Drug-Eluting Sinus Stents and Implants for Postoperative Use Following Endoscopic Sinus Surgery and for Recurrent Sinonasal Polyposis is addressed separately in medical policy 00485.

Note: Balloon Dilation of the Eustachian Tube is addressed separately in medical policy 00613.

When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Based on review of available data, the Company may consider sinus ostial dilatation with balloon catheter for the treatment of chronic rhinosinusitis or recurrent acute rhinosinusitis to be **eligible for coverage**.**

Patient Selection Criteria for chronic rhinosinusitis

Coverage eligibility will be met when the following criteria are present:

- Individual is 13 years of age or older; **AND**
- Documentation supports absence of nasal polyps or tumors; **AND**
- Chronic rhinosinusitis symptoms persisted for a minimum of 12 weeks despite aggressive medical therapy; **AND**
- Documentation of treatment with **ALL** of the following:
 - Saline nasal irrigation for at least 8 consecutive weeks
 - Intranasal corticosteroids for at least 8 weeks
 - Two 10-day courses of antibiotics or one prolonged course of oral antibiotic for at least 21 days; **AND**

Balloon Catheter use for Sinus Ostial Dilation and Septoplasty

Policy # 00292

Original Effective Date: 04/13/2011

Current Effective Date: 05/01/2026

Retired Date: 02/15/2012

Returned to Active Status: 12/01/2015

- Chronic rhinosinusitis is confirmed with nasal endoscopy and computed tomography as evidenced by:
 - Purulent (not clear) mucus OR edema in the middle meatus, anterior ethmoid, or sphenoethmoid region; **AND**
 - Significant mucosal thickening of greater than 3 mm, opacification, or air-fluid levels in the sinus to be dilated is documented by a formal CT scan report from an independent radiologist.

Patient Selection Criteria for recurrent acute rhinosinusitis

Coverage eligibility will be met when the following criteria are present:

- Individual is 13 years of age or older; **AND**
- Documentation supports absence of nasal polyps or tumors; **AND**
- Four or more documented and treated episodes in a 12-month period with interim symptom resolution; **AND**
- Nasal endoscopy performed during the fourth episode showing purulent (not clear) mucus OR edema in the middle meatus, anterior ethmoid, or sphenoethmoid region; **AND**
- CT imaging performed during the fourth episode should demonstrate pathology in the sinus to be dilated that meets the same CT imaging criteria (significant mucosal thickening of greater than 3 mm, opacification, or air-fluid levels documented by a formal CT scan report from an independent radiologist.)

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

The use of sinus ostial dilatation with balloon catheter when patient selection criteria are not met is considered to be **investigational**.*

Based on review of available data, the Company considers sinus ostial dilatation with balloon catheter for the treatment of nasal polyps or tumors to be **investigational**.*

Based on review of available data, the Company considers sinus ostial dilatation with balloon catheter for children ages 12 and under to be **investigational**.*

Based on review of available data, the Company considers dilation of sinus ostia using a device other than balloon catheter, including but not limited to reusable dilators (e.g. Simplicity[®]† Dilators), to be **investigational**.*

Based on review of available data, the Company considers the use of balloon catheter dilation for septoplasty to be **investigational**.*

Balloon Catheter use for Sinus Ostial Dilation and Septoplasty

Policy # 00292

Original Effective Date: 04/13/2011

Current Effective Date: 05/01/2026

Retired Date: 02/15/2012

Returned to Active Status: 12/01/2015

Policy Guidelines

Classification of rhinosinusitis is based upon symptom duration:

- Acute rhinosinusitis – Symptoms for less than 4 weeks
- Subacute rhinosinusitis – Symptoms for 4 to 12 weeks
- Chronic rhinosinusitis – Symptoms persist greater than 12 weeks
- Recurrent acute rhinosinusitis – Four or more documented and treated episodes of acute rhinosinusitis in a 12-month period, with interim symptom resolution

When indicated and appropriate, optimal medical therapy should include also:

- Allergy evaluation, education, and optimal treatment;
- Decongestants;
- Treatment of rhinitis medicamentosa (rebound nasal congestion due to extended use of topical decongestants);
- Education on environmental irritants including tobacco smoke.

Balloon Ostial Dilation (BOD) used in combination with Functional Endoscopic Sinus Surgery (FESS)

- BOD when used as a tool during functional endoscopic sinus surgery (FESS) in the same sinus cavity is considered to be an integral part of the FESS procedure.
- When BOD is used as an adjunct to FESS (defined as FESS on one sinus and BOD on another sinus in the same patient during the same operation) medical necessity criteria for BOD apply to the sinus being considered for BOD.

Considerations for the use of BOD in children under age 18 years include the following:

- FDA labeling for several 510(k) cleared devices includes use in children 17 years of age and under and is indicated to dilate sinus ostia and spaces associated with the maxillary sinus for diagnostic and therapeutic procedures.
- A 2014 AAO-HNS Clinical Consensus Statement on Pediatric Chronic Rhinosinusitis had near consensus on the safety of BOD in children but did not reach a consensus on efficacy.
- American Academy of Pediatrics Clinical Practice Guidelines only address the diagnosis and treatment of acute bacterial rhinosinusitis.

According to the 2015 American Academy of Otolaryngology - Head and Neck Surgery (AAO-HNS) guideline on adult sinusitis, abnormal findings on CT imaging may include moderate-to-severe mucosal thickening, opacification, or air-fluid levels. A subsequent consensus statement on balloon dilation of the sinuses published by the AAO-HNS in 2018 states: "The requirement of objective evidence of inflammation in addition to sinonasal symptoms suggestive of rhinosinusitis is consistent with AAO-HNSF diagnostic criteria for rhinosinusitis. However, evidence of inflammation or other findings on a CT scan was not deemed sufficient alone to make a patient a candidate for balloon dilation. The consensus that both symptoms and objective evidence of sinonasal disease are needed to deem a patient appropriate for a SOD [sinus ostial dilation] procedure

Balloon Catheter use for Sinus Ostial Dilation and Septoplasty

Policy # 00292

Original Effective Date: 04/13/2011

Current Effective Date: 05/01/2026

Retired Date: 02/15/2012

Returned to Active Status: 12/01/2015

is also reflected in many of the randomized clinical trials involving balloon dilation. The inclusion criteria for many of these trials require that the patient be deemed appropriate for conventional sinus surgery, which includes a trial of medical therapy and the presence of sinonasal symptoms in addition to objective evidence of sinus mucosal inflammation. On the surface, this statement may seem incompatible with the guidelines that mandate the presence of objective findings but do not specify which objective findings those are (i.e., polyps, purulence, or CT findings) for the diagnosis of CRS. However, the panel felt that the transition from diagnosis to management requires additional information. In that vein, a CT scan is necessary before proceeding with surgical management, and the findings of that CT scan would direct which sinuses were to be addressed. It was also agreed that an improved taxonomy for the classification of sinusitis would be helpful to improve the quality of clinical research."

For individuals undergoing evaluation for surgical management of chronic sinusitis (either dilation or standard functional endoscopic sinus surgery), the CT scan on which the surgical plan and evaluation are based is typically performed within 90 days of the planned procedure. CT scans beyond 90 days may be repeated, as both disease and anatomy may have changed. CT scans older than 90 days may rarely be used in adult individuals when the symptoms and/or condition have not changed since the CT scan was obtained.

When assessing for response to therapy and potential surgical candidacy for individuals with chronic rhinosinusitis, CT scanning is typically indicated approximately 1-2 weeks following completion of aggressive medical therapy. Imaging prior to this time may underrepresent patient response and overrepresent disease burden. However, in certain circumstances, such as in lack of response to treatment or uncertainty of diagnosis, imaging may be indicated earlier in the treatment course or even prior to the initiation of treatment.

Background/Overview

The balloon ostial dilatation procedure involves placing a balloon in the sinus ostium and inflating the balloon to stretch the opening. It can be performed as a stand-alone procedure or as an adjunctive procedure to FESS.

Chronic rhinosinusitis (CRS) is characterized by purulent nasal discharge, usually without fever, that persists for weeks to months. Symptoms of congestion often accompany the nasal discharge. There also may be mild pain and/or headache. Thickening of mucosa may restrict or close natural openings between sinus cavities and the nasal fossae, although symptoms are variable because considerable variation exists in the location and shape of these sinus ostia.

Recurrent acute rhinosinusitis (RARS) is defined as 4 or more episodes per year of acute bacterial rhinosinusitis without signs or symptoms of rhinosinusitis between episodes.

Balloon Catheter use for Sinus Ostial Dilatation and Septoplasty

Policy # 00292

Original Effective Date: 04/13/2011

Current Effective Date: 05/01/2026

Retired Date: 02/15/2012

Returned to Active Status: 12/01/2015

Most cases of CRS and RARS are treated with medical therapy (e.g., antihistamines, steroids, nasal lavage, and antibiotics). Additionally, an anti-interleukin-5 (IL-5) monoclonal antibody (mAb), mepolizumab, received FDA-approval in July 2021 as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps. Previously in 2019, the FDA approved the interleukin-4 receptor alpha antagonist dupilumab as an add-on maintenance treatment in adults with inadequately controlled chronic rhinosinusitis with nasal polyps.

Balloon ostial dilatation can be used as an alternative or as an adjunct to FESS for those with CRS or RARS. The goal of this technique, when used as an alternative to FESS, is to improve sinus drainage using a less invasive approach. The procedure involves placing a guidewire in the sinus ostium, advancing a balloon over the guidewire, and then stretching the opening by inflating the balloon. The guidewire location is confirmed with fluoroscopy or with direct transillumination of the targeted sinus cavity. General anesthesia may be needed for this procedure to minimize patient movement. According to the manufacturer, the RELIEVA SPINPLUS[®] Balloon Sinuplasty System is intended to: provide a means to access the sinus space and illuminate within and transilluminate across nasal and sinus structures; dilate the sinus ostia and spaces associated with the paranasal sinus cavities for diagnostic and therapeutic procedures; and irrigate from within a target sinus for therapeutic procedures and to facilitate diagnostic procedures.

This evidence review is limited to BOD when used as a standalone procedure. BOD may also be used in combination with FESS. When used as an adjunct to FESS, it is intended to facilitate and/or increase access to the sinuses. BOD may also be used on 1 sinus and FESS on another sinus in the same patient during the same operation.

Estimates are that approximately 30 million individuals in the United States suffer from chronic sinusitis. Most cases are treated with medical therapy, but surgical drainage is an option for individuals who fail to respond to medical therapy. Functional endoscopic sinus surgery has become an important aspect for surgical management of chronic sinusitis. For this procedure, a fiberoptic nasal endoscope is used to visualize the sinus ostia, and any obstruction found is corrected. This procedure restores patency and allows air and mucous transport through the natural ostium. Approximately 350,000 FESS procedures are done each year in the United States for chronic sinusitis.

A newer procedure, balloon ostial dilatation can be used as an alternative to FESS or as an adjunct to FESS for those with chronic sinusitis. The goal of this technique, when used as an alternative to FESS, is to achieve improved sinus drainage using a less invasive approach. When used as an adjunct to FESS, it is intended to facilitate and/or increase access to the sinuses. The procedure involves placing a guidewire in the sinus ostium, advancing a balloon over the guidewire, and then stretching the opening by inflating the balloon. The guidewire location is confirmed with fluoroscopy or with direct transillumination of the targeted sinus cavity. General anesthesia may be needed for this procedure to minimize patient movement.

Balloon Catheter use for Sinus Ostial Dilation and Septoplasty

Policy # 00292

Original Effective Date: 04/13/2011

Current Effective Date: 05/01/2026

Retired Date: 02/15/2012

Returned to Active Status: 12/01/2015

The maxillary sinus creates a unique challenge. The maxillary ostia, located within the ethmoid infundibulum, often cannot be accessed transnasally without excising a portion of the uncinate process. An alternate approach to the maxillary ostia is through the sinus, via the canine fossa. A guidewire can be advanced from within the maxillary sinus to the nasal fossa. The dilating balloon can enlarge the ostia while deflecting the uncinate process.

Recently marketed reusable stainless steel dilators (e.g. Simplicity[®] ‡ Dilators) may be comparable to balloon ostial dilators, however published evidence is insufficient at this time to support long-term efficacy and safety with their use, and confirm appropriate patient selection. In addition, there is not enough data comparing these reusable dilators to balloon dilation catheters cleared by FDA.

Septoplasty is traditionally performed in an endonasal fashion through an incision. In select cases septoplasty may be performed as an “open” or external approach to completely address a septal deviation, especially in circumstances where there is substantial caudal deviation or dorsal septal deviation or in cases where a large amount of cartilage must be removed, reshaped, and replaced. Endoscopic septoplasty has been shown to be equivalent to “open” septoplasty, as well as to demonstrate fewer complications and decreased operative time.

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

In 2008, the Relieva[™] ‡ Sinus Balloon Catheter (Integra LifeSciences, formerly Acclarent Inc.) was cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process. FDA determined that this device was substantially equivalent to existing devices for use in dilating the sinus ostia and paranasal spaces in adults and maxillary sinus spaces in children. Subsequent devices developed by Acclarent have also been cleared by FDA through the 510(k) process (see Table 1 below).

In 2008, the FinESS[™] ‡ Sinus Treatment (Entellus Medical, Maple Grove, MN) was cleared for marketing by FDA through the 510(k) process. The indication noted is to access and treat the maxillary ostia/ethmoid infundibulum in adults using a transantral approach (FDA product code: EOB). The bony sinus outflow tracts are remodeled by balloon displacement of adjacent bone and paranasal sinus structures. Two other balloon sinus ostial dilation devices, the ENTrigue[®] ‡ Sinus Dilation System (Smith & Nephew, formerly ENTrigue Surgical), and the XprESS[™] ‡ Multi-Sinus Dilation Tool (Stryker, formerly Entellus Medical), also received 510(k) clearance in 2012.

In 2013, a sinus dilation system (Medtronic Xomed, Jacksonville, FL), later named the NuVent[™] ‡ EM Balloon Sinus Dilation System, was cleared for marketing by FDA through the 510(k) process for use in conjunction with a Medtronic computer-assisted surgery system when surgical navigation or image-guided surgery may be necessary to locate and move tissue, bone, or cartilaginous tissue surrounding the drainage pathways of the frontal, maxillary, or sphenoid sinuses.

Balloon Catheter use for Sinus Ostial Dilation and Septoplasty

Policy # 00292

Original Effective Date: 04/13/2011

Current Effective Date: 05/01/2026

Retired Date: 02/15/2012

Returned to Active Status: 12/01/2015

Also in 2013, a sinus dilation system (Smith & Nephew), later named the Ventera^{TM‡} Sinus Dilation System, was cleared for marketing through the 510(k) process to access and treat the frontal recesses, sphenoid sinus ostia, and maxillary ostia/ethmoid infundibula in adults using a transnasal approach. Ventera^{TM‡} Sinus Dilation System does not require a guide wire or an illumination system as it is intended for use as a tool in combination with endoscopic sinus surgery.

Table 1 summarizes a selection of FDA cleared balloon sinus dilation devices.

FDA product code: LRC.

Table 1. Balloon Ostial Dilation Devices Cleared by the U.S. Food and Drug Administration

Device	Manufacturer	510(k) No.	Date Cleared	Indication
Relieva Ultirra Sinus Balloon Catheter	Acclarent, Inc.	K190525	05/03/2019	Sinus Ostia Dilation
Sinusway Dilation System	3NT Medical Ltd.	K181838	12/20/2018	Sinus Ostia Dilation
MESIRE - Balloon Sinus Dilatation System	Meril Life Sciences	K172737	12/12/2017	Sinus Ostia Dilation
Relieva SpinPlus Nav Balloon Sinuplasty System	Acclarent, Inc.	K171687	10/13/2017	Sinus Ostia Dilation
Relieva UltirraNav Sinus Balloon Catheter	Acclarent Inc.	K161698	10/24/2016	Sinus Ostia Dilation
Vent-Os Sinus Dilation Family	Sinusys Corp.	K160770	6/29/2016	Sinus Ostia Dilation
Relieva Scout Multi-Sinus Dilation System	Acclarent Inc.	K153341	2/12/2016	Sinus Ostia Dilation
XprESS Multi-Sinus Dilation System	Entellus Medical Inc.	K152434	11/20/2015	Sinus Ostia Dilation
DSS Sinusplasty Balloon Catheter	Intuit Medical Products LLC	K143738	8/27/2015	Sinus Ostia Dilation
Relieva SpinPlus Balloon Sinuplasty System	Acclarent Inc.	K143541	4/22/2015	Sinus Ostia Dilation
XprESS Multi-Sinus Dilation Tool	Entellus Medical Inc.	K142252	10/17/2014	Sinus Ostia Dilation

Balloon Catheter use for Sinus Ostial Dilation and Septoplasty

Policy # 00292

Original Effective Date: 04/13/2011

Current Effective Date: 05/01/2026

Retired Date: 02/15/2012

Returned to Active Status: 12/01/2015

Relieva Scout Multi-Sinus Dilation System	Acclarent Inc.	K140160	2/20/2014	Sinus Ostia Dilation
---	----------------	---------	-----------	----------------------

Simplicity[®]‡ Solid Dilators and Simplicity[®]‡ Suction Dilators were registered with the FDA in 2020. According to manufacturer's website, "Simplicity Dilators are made from medical grade stainless steel parts, which are easily cleaned and sterilized for multiple uses." "Simplicity Dilators do not require cutting of nasal bone or tissue nor any manipulation or inflation of extended devices. During sinus dilation, a Simplicity dilator is positioned and used to gently open the sinus passageways, facilitating drainage of the mucus buildup."

Rationale/Source

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to regulations, other plan medical policies, and accredited national guidelines.

Balloon ostial dilation (BOD, also known as balloon sinuplasty) is proposed as an alternative to functional endoscopic sinus surgery (FESS) for individuals with chronic rhinosinusitis (CRS) or recurrent acute rhinosinusitis (RARS) who fail medical management. The procedure involves placing a balloon in the sinus ostium and inflating the balloon to stretch the opening. It can be performed as a stand-alone procedure or as an adjunctive procedure to FESS. This evidence review addresses BOD as a standalone procedure.

For individuals with CRS who receive BOD as a stand-alone procedure, the evidence includes a systematic review, randomized controlled trials (RCTs), and observational studies. Relevant outcomes are symptoms, change in disease status, quality of life, and treatment-related morbidity. A meta-analysis of three studies indicated a statistically significant yet not clinically significant preference for BOD over FESS in terms of patient-related quality of life. The REMODEL RCT confirmed that BOD was not inferior to FESS for treating chronic rhinosinusitis, with the effect's durability observed over 24 months. In a retrospective cohort study that used data from a large commercial insurance database to examine adverse events in individuals who underwent BOD (n=2851) or FESS (n=11,955), the overall complication rate was 5% with BOD and 7% with FESS. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with RARS who receive BOD as a stand-alone procedure, the evidence includes a systematic review and RCTs. Relevant outcomes are symptoms, change in disease status, quality of life, and treatment-related morbidity. A systematic review on RARS management identified two (of 10) studies focused on BOD as a treatment modality. Although an improvement in quality of life was observed across both studies, the small sample sizes, diverse outcome measures, and study

Balloon Catheter use for Sinus Ostial Dilation and Septoplasty

Policy # 00292

Original Effective Date: 04/13/2011

Current Effective Date: 05/01/2026

Retired Date: 02/15/2012

Returned to Active Status: 12/01/2015

heterogeneity prevented the authors from conducting a meta-analysis. In the REMODEL RCT, 32% of participants (N=29) with RARS were diagnosed. BOD was found to be non-inferior to FESS in terms of quality of life at both 6- and 12-months post-procedure. Another RCT, CABERNET, comparing BOD plus medical care to medical care alone in individuals with RARS (N=59), demonstrated significantly improved quality of life and fewer sinus infections after 6 months in the balloon dilation group. The current body of evidence is limited by small sample sizes, unblinded outcome assessment, lack of appropriate comparators, and heterogeneity in outcome measures. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with septal deviation who receive balloon septoplasty, the evidence includes a case report. Relevant outcomes are symptoms, change in disease status, quality of life, and treatment-related morbidity. A case report was published in Journal of Neurosurgical Case Lessons (September 2022) on use of balloon-assisted nasal access to augment endoscopic endonasal transsphenoidal approach (an illustrative case). Authors noted that long-term durability of balloon septoplasty is not relevant to surgical access to the sella and skull base region. Melroy et al. reported a complication rate of 0.0035% per sinus when reviewing orbital and cranial complications associated with balloon ostial dilation in the FDA database.

There is insufficient scientific evidence to support efficacy, safety, durability and improved net health outcomes with use of balloon septoplasty as compared to current standard medical and surgical care.

Supplemental Information

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American Academy of Otolaryngology – Head and Neck Surgery et al

In 2018, the American Academy of Otolaryngology - Head and Neck Surgery (AAO-HNS) published a clinical consensus statement on balloon dilation of the sinuses. Participating subgroups included the Triologic Society, the American Rhinologic Society, the American Academy of Otolaryngic Allergy, and the American Academy of Allergy, Asthma & Immunology. The expert panel used Delphi method surveys to assess consensus on proposed statements. Statements achieving a mean score of 7.00 or higher and having no more than 1 outlier (2 or more Likert points from the mean in either direction) met criteria for consensus. Strong consensus was defined as a mean Likert score of 8.00 or higher with no outliers. The following statements met consensus; statements

Balloon Catheter use for Sinus Ostial Dilation and Septoplasty

Policy # 00292

Original Effective Date: 04/13/2011

Current Effective Date: 05/01/2026

Retired Date: 02/15/2012

Returned to Active Status: 12/01/2015

reaching strong consensus are emphasized below. The updated information to guideline statement can be found on the AAO-HNS website dated April 2021.

Patient Criteria:

- Balloon dilation is not appropriate for patients who are without both sinonasal symptoms and positive findings on CT. (Strong consensus)
- Balloon dilation is not appropriate for the management of headaches in patients who do not otherwise meet the criteria for chronic sinusitis or recurrent acute sinusitis. (Strong consensus)
- Balloon dilation is not appropriate for the management of sleep apnea in patients who do not otherwise meet the criteria for chronic sinusitis or recurrent acute sinusitis. (Strong consensus)
- CT scanning of the sinuses is a requirement before balloon dilation can be performed. (Strong consensus)
- Balloon dilation is not appropriate for patients with sinonasal symptoms and a CT that does not show evidence of sinonasal disease.
- Balloon dilation can be appropriate as an adjunct procedure to FESS in patients with chronic sinusitis without nasal polyps.
- There can be a role for balloon dilation in patients with persistent sinus disease who have had previous sinus surgery.
- There is a role for balloon sinus dilation in managing patients with recurrent acute sinusitis as defined in the AAO-HNSF guideline based on symptoms and CT evidence of ostial occlusion and mucosal thickening.

Perioperative Considerations:

- Surgeons who consider reusing devices intended for dilation of the sinuses should understand the regulations set forth by the U.S. Food and Drug Administration for reprocessing such devices and ensure that they are followed. (Strong consensus)
- Balloon dilation can be performed under any setting as long as proper precautions are taken and appropriate monitoring is performed.
- Balloon dilation can be performed under local anesthesia with or without sedation.

Outcome:

- Balloon dilation can improve short-term quality-of-life outcomes in patients with limited CRS without polyposis.
- Balloon dilation can be effective in frontal sinusitis.

The AAO-HNS updated its statement on balloon ostial dilation, reaffirming its 2010 position statement: “Sinus ostial dilation ... is a therapeutic option for selected patient with chronic rhinosinusitis.... This approach may be used alone... or in conjunction with other instruments....” (Most recent revision with references added, 4/13/2021)

Balloon Catheter use for Sinus Ostial Dilation and Septoplasty

Policy # 00292

Original Effective Date: 04/13/2011

Current Effective Date: 05/01/2026

Retired Date: 02/15/2012

Returned to Active Status: 12/01/2015

In 2025, the AAO-HNS updated its clinical practice guidelines on adult sinusitis, which do not discuss surgical therapy or use of balloon sinuplasty. However, surgical therapy is addressed in 2025 guidelines on chronic rhinosinusitis from AAO-HNS, but these guidelines do not address balloon sinuplasty.

American Academy of Otolaryngology – Head and Neck Surgery et al

The 2015 Clinical Consensus Statement (Septoplasty with or without inferior turbinate reduction) defined nasal septoplasty as a surgical procedure designed to correct a deviated nasal septum for the purpose of improving nasal function, form, or both. For the surgical aspects of septoplasty, 3 statements reached consensus. Consensus was reached that an external rhinoplasty approach may be necessary in cases of severe septal deviation. The panel also reached consensus that septoplasty may be necessary as a surgical component in the repair of septal perforations. Last, the panel reached consensus that endoscopic visualization during septoplasty can assist the surgeon in correcting posterior septal deviations. There is no mention of balloon septoplasty in this consensus statement or other professional society guidelines.

National Institute for Health and Care Excellence

In 2008 (reaffirmed in 2012), a guidance on balloon catheter dilation of paranasal sinus ostia from the National Institute for Health and Care Excellence (NICE) stated:

- "Current evidence on the short-term efficacy of balloon catheter dilation of paranasal sinus ostia for chronic sinusitis is adequate and raises no major safety concerns.
- This procedure should only be carried out by surgeons with experience of complex sinus surgery, and specific training in both the procedure and the use of fluoroscopy.
- Publication of long-term outcomes will be helpful in guiding the future use of this technique. NICE may review the procedure upon publication of further evidence."

In 2016, NICE published a recommendation on the use of the XprESS Multi-Sinus Dilation System for the treatment of chronic rhinosinusitis:

- 1.1 "The case for adopting the XprESS multi-sinus dilation system for treating uncomplicated chronic sinusitis after medical treatment has failed is supported by the evidence. Treatment with XprESS leads to a rapid and sustained improvement in chronic symptoms, fewer acute episodes and improved quality of life which is comparable to functional endoscopic sinus surgery (FESS).
- 1.2 XprESS should be considered in patients with uncomplicated chronic sinusitis who do not have severe nasal polyposis. In these patients, XprESS works as well as FESS, is associated with faster recovery times, and can more often be done under local anaesthesia."

The recommendation was based on the results of the REMODEL study: the committee "considered that the evidence from REMODEL demonstrated that balloon dilation (with either XprESS or FinESS) is clinically non-inferior to FESS in terms of alleviating symptoms in patients with

Balloon Catheter use for Sinus Ostial Dilation and Septoplasty

Policy # 00292

Original Effective Date: 04/13/2011

Current Effective Date: 05/01/2026

Retired Date: 02/15/2012

Returned to Active Status: 12/01/2015

uncomplicated chronic sinusitis." Single-arm observational studies were of lower quality but were consistent with the findings of the REMODEL study. This guidance was reaffirmed in July 2020.

American Rhinologic Society

A position statement, revised in 2023, from the American Rhinologic Society, stated that sinus ostial dilation is "a therapeutic option for selected patients with chronic rhinosinusitis (CRS) and recurrent acute rhinosinusitis (RARS) who have failed appropriate medical therapy."

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials

Some currently unpublished trials that might influence this review are listed in Table 2.

Table 2. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
<i>Ongoing</i>			
NCT04645511	A Placebo Controlled Randomized Study of the Balloon Sinuplasty Efficiency in Chronic or Recurrent Maxillary Rhinosinusitis	120	Dec 2027 (last update posted: Oct 2022)

NCT: national clinical trial.

References

1. Zinreich, James S. Imaging for Staging of Rhinosinusitis. *Ann Otol Rhinol Laryngol*. 2004; 113:19-23.
2. Langille, Morgan M.D. et al. Frontal sinus cells: Identification, prevalence, and association with frontal sinus mucosal thickening. *American Journal of Rhinology and Allergy*. 2012; 26:e107-e110.
3. Rak, Kevin M. et al. Paranasal Sinuses on MR Images of the Brain: Significance of Mucosal Thickening. *AJNR*:11 1990:1211-1214.
4. Piccirillo, Jay F. et al. Clinical Consensus Statement: Balloon Dilation of the Sinuses. *Clinical Consensus Statement. Otolaryngology-Head and Neck Surgery*. 2018 158(2) 203-214.
5. U.S. Food and Drug Administration. Establishment Registration and Device Listing. 08/03/2020.

Balloon Catheter use for Sinus Ostial Dilation and Septoplasty

Policy # 00292

Original Effective Date: 04/13/2011

Current Effective Date: 05/01/2026

Retired Date: 02/15/2012

Returned to Active Status: 12/01/2015

6. Christopher T. Melroy MD. Savannah,GA. The balloon dilating catheter as an instrument in sinus surgery. Otolaryngology-Head and Neck Surgery (2008),S23-S26. Commentary.
7. Becker SS, Dobratz EJ, Stowell N, et al. Revision septoplasty:review of sources of persistent nasal obstruction. Am J Rhinol.2008;22:440-444.
8. Hwang PH, McLaughlin RB, Lanza DC, et al. Endoscopic sep-toplasty: indications, technique, and results. Otolaryngol HeadNeck Surg. 1999;120:678-682
9. Paradis J, Rotenberg BW. Open versus endoscopic septoplasty:a single-blinded, randomized, controlled trial. J OtolaryngolHead Neck Surg. 2011;40(suppl 1):S28-S33.29. 10. Bothra R, Mathur NN. Comparative evaluation of conventionalversus endoscopic septoplasty for limited septal deviation andspur. J Laryngol Otol. 2009;123:737-741
10. Nolan Winslow et al. Use of balloon-assisted nasal access to augment endoscopic endonasal transsphenoidal approach: illustrative case. NIH National Library of Medicine. J Neurosurg Case Lessons. 2022 Sep 5;4(10):CASE22276. doi: 10.3171/CASE22276.
11. Joseph K. Han MD et al. Clinical Consensus Statement:Septoplasty with or without InferiorTurbinates Reduction. Clinical Consensus Statement. American Academy of Otolaryngology-Head and Neck Surgery.

Policy History

Original Effective Date: 04/13/2011

Current Effective Date: 05/01/2026

04/07/2011 Medical Policy Committee review

04/13/2011 Medical Policy Implementation Committee approval. New policy.

02/15/2012 Policy Retired.

09/03/2015 Medical Policy Committee review

09/23/2015 Medical Policy Implementation Committee approval. Title change, patient selection criteria added. Policy rewritten. Policy returned to active status.

02/04/2016 Medical Policy Committee review

02/17/2016 Medical Policy Implementation Committee approval. Added the requirement of at least 2 weeks of antibiotics and significant mucosal thickening of at least 2 mm prior to approval. Also clarified age of children 12 years and under is considered to be investigational.

06/02/2016 Medical Policy Committee review

06/20/2016 Medical Policy Implementation Committee approval. Patient selection criteria revised to this:

Coverage eligibility will be met when the following criteria are present:

- Chronic rhinosinusitis in an adult which has persisted for a minimum of 12 weeks despite failure of aggressive medical therapy. This should include documentation of treatment with all of the following:
 - o Saline nasal irrigations
 - o Intranasal corticosteroids for at least 8 weeks
 - o Two courses of antibiotics

Balloon Catheter use for Sinus Ostial Dilation and Septoplasty

Policy # 00292

Original Effective Date: 04/13/2011

Current Effective Date: 05/01/2026

Retired Date: 02/15/2012

Returned to Active Status: 12/01/2015

- Chronic rhinosinusitis of the sinus to be dilated is confirmed on computed tomography as evidenced by significant mucosal thickening of 4 mm or greater, opacification or air-fluid levels as evidenced by a formal CT scan report from an independent radiologist.

09/08/2016 Medical Policy Committee review

09/21/2016 Medical Policy Implementation Committee approval. Criteria revised to:

Patient Selection Criteria for chronic rhinosinusitis

Coverage eligibility will be met when the following criteria are present:

- Chronic rhinosinusitis in an adult which has persisted for a minimum of 12 weeks despite failure of aggressive medical therapy. This should include documentation of treatment with all of the following:
 - Saline nasal irrigations or saline nasal spray
 - Intranasal corticosteroids for at least 8 weeks
 - Two courses of antibiotics or one prolonged course of oral antibiotic for at least 21 days
- Chronic rhinosinusitis of the sinus to be dilated is confirmed on computed tomography as evidenced by significant mucosal thickening of greater than 3 mm, opacification, or air-fluid levels documented by a formal CT scan report from an independent radiologist.

Recurrent acute rhinosinusitis criteria added to the policy. “Chronic” removed from title.

01/01/2017 Coding update: Removing ICD-9 Diagnosis Codes

06/01/2017 Medical Policy Committee review

06/21/2017 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

06/07/2018 Medical Policy Committee review

06/20/2018 Medical Policy Implementation Committee approval. No change to coverage.

06/06/2019 Medical Policy Committee review

06/19/2019 Medical Policy Implementation Committee approval. No change to coverage.

08/06/2020 Medical Policy Committee review

08/12/2020 Medical Policy Implementation Committee approval. Added the following changes under the Patient Selection Criteria for chronic rhinosinusitis section:

- Chronic rhinosinusitis without nasal polyps in an adolescent or adult patient, which has persisted for a minimum of 12 weeks despite aggressive medical therapy. This should include documentation of treatment with all of the following:
 - Saline nasal irrigation for at least 8 consecutive weeks
 - Two 10-day courses of antibiotics or one prolonged course of oral antibiotic for at least 21 days; AND
- Chronic rhinosinusitis of the sinus to be dilated is confirmed with nasal endoscopy and computed tomography as evidenced by:

Balloon Catheter use for Sinus Ostial Dilation and Septoplasty

Policy # 00292

Original Effective Date: 04/13/2011

Current Effective Date: 05/01/2026

Retired Date: 02/15/2012

Returned to Active Status: 12/01/2015

- Purulent (not clear) mucus OR edema in the middle meatus, anterior ethmoid, or sphenoethmoid region; AND

Added the following changes under the Patient Selection Criteria for recurrent acute rhinosinusitis section:

- Nasal endoscopy performed during the fourth episode showing purulent (not clear) mucus OR edema in the middle meatus, anterior ethmoid, or sphenoethmoid region;

Added the following investigational statements:

The use of sinus ostial dilatation with balloon catheter when patient selection criteria are not met is considered to be investigational. and

Based on review of available data, the Company considers dilation of sinus ostia using a device other than balloon catheter, including but not limited to reusable dilators (e.g. Simplicity® Dilators), to be investigational.

Policy guidelines added to policy.

08/05/2021 Medical Policy Committee review

08/11/2021 Medical Policy Implementation Committee approval. No change to coverage.

08/04/2022 Medical Policy Committee review

08/10/2022 Medical Policy Implementation Committee approval. Statement added to policy guidelines section.

08/03/2023 Medical Policy Committee review

08/09/2023 Medical Policy Implementation Committee approval. No change to coverage.

08/01/2024 Medical Policy Committee review

08/14/2024 Medical Policy Implementation Committee approval. No change to coverage. Policy Guidelines, FDA and supplemental information updated.

04/03/2025 Medical Policy Committee review

04/09/2025 Medical Policy Implementation Committee approval. Added “Based on review of available data, the Company considers the use of balloon catheter dilation for septoplasty to be investigational. Title changed from “Sinus Ostial Dilatation with Balloon Catheter for Rhinosinusitis” to “Balloon Catheter use for Sinus Ostial Dilation and Septoplasty”.

04/02/2026 Medical Policy Committee review

04/10/2026 Medical Policy Implementation Committee approval. Added these criteria bullets for chronic rhinosinusitis: Individual is 13 years of age or older; AND Documentation supports absence of nasal polyps or tumors; AND Chronic rhinosinusitis symptoms persisted for a minimum of 12 weeks despite aggressive medical therapy.

This criteria bullet was changed to “Significant mucosal thickening of greater than 3 mm, opacification, or air-fluid levels in the sinus to be dilated is documented by a formal CT scan report from an independent radiologist.”

Added the following bullets to recurrent acute rhinosinusitis criteria: Individual is 13 years of age or older; AND Documentation supports absence of nasal polyps or tumors.

Balloon Catheter use for Sinus Ostial Dilation and Septoplasty

Policy # 00292

Original Effective Date: 04/13/2011

Current Effective Date: 05/01/2026

Retired Date: 02/15/2012

Returned to Active Status: 12/01/2015

Next Scheduled Review Date: 04/2027

Coding

The five character codes included in the Louisiana Blue Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)†, copyright 2025 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Louisiana Blue Medical Policy Coverage Guidelines is with Louisiana Blue and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Louisiana Blue Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Louisiana Blue Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	30999, 31295, 31296, 31297, 31298, 31299
HCPCS	C1726
ICD-10 Diagnosis	All related diagnoses

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety,

Balloon Catheter use for Sinus Ostial Dilation and Septoplasty

Policy # 00292

Original Effective Date: 04/13/2011

Current Effective Date: 05/01/2026

Retired Date: 02/15/2012

Returned to Active Status: 12/01/2015

effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

1. Consultation with technology evaluation center(s);
2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

****Medically Necessary (or “Medical Necessity”)** - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

NOTICE: Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage.

NOTICE: If an authorization for an ongoing course of treatment has been provided to a member and the member changes from one health plan to another health plan (e.g., a member moves from carrier A to Louisiana Blue), Louisiana Blue may honor the previous health plan’s authorization for

Balloon Catheter use for Sinus Ostial Dilation and Septoplasty

Policy # 00292

Original Effective Date: 04/13/2011

Current Effective Date: 05/01/2026

Retired Date: 02/15/2012

Returned to Active Status: 12/01/2015

the same service under the same type of in-network benefit for a 90-day transition period. Documentation of the authorization for the ongoing course of treatment from the previous health plan must be provided to us by the member or their provider and the services provided for the course of treatment must otherwise be a covered service under the Louisiana Blue health plan. This provision does not apply to medications covered under the plan's pharmacy benefit.